logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Sunshine Biopharma's New mRNA Therapeutics Killed Cancer Cells with Little or No Adverse Effects

Sunshine Biopharma mRNA Therapeutics Effective at Destroying Cancer Cells Sunshine Biopharma, Inc. ( SBFM ) -  a pharmaceutical company focused on research, development and commercialization of oncology and antiviral drugs, announced that two of its newly designed mRNA molecules are...

Read More

April 5, 2022

0

Italfarmaco Received FDA Approval for Duvyzat™ for the Treatment of Duchenne Muscular Dystrophy

Italfarmaco in the NEWS  From Milan, Italy: Today, Italfarmaco announced that the U.S. Food and Drug Administration ( FDA ) has approved Duvyzat™ (givinostat) - a novel histone deacetylase ( HDAC ) inhibitor, for the treatment of patients 6 years or...

Read More

March 22, 2024

0

Mitsubishi Tanabe Pharma America Announced the Presentations of its ND0612 in Parkinson’s Disease at 10th Congress of the European Academy of Neurology  

From Mitsubishi Tanabe Pharma America Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at Mitsubishi Tanabe Pharma America said, “We are excited to be at the Congress of the European Academy of Neurology ( EAN ) this year...

Read More

June 28, 2024

0

Eisai and Biogen: Lecanemab for the Treament of Early Alzheimer's DIisease

Eisai and Biogen Inc: Lecanemab Eisai  and Biogen Inc. ( BIIB ) announced that Eisai has completed the rolling submission to the U.S. FDA of a Biologics License Application ( BLA ) under the accelerated approval pathway for the investigational...

Read More

May 10, 2022

0

SCG Cell Therapy: FDA Approved IND Application of Product SCG142 to Initiate Phase 1/2 Clinical Trial for A Next Generation HPV and its cancers.

SCG Cell Therapy FDA Approval SCG Cell Therapy Pte Ltd (SCG) is a biotech company developing novel immunotherapies for infectious diseases and their associated cancers, announced that United States FDA has approved its investigational New Drug ( IND ) application...

Read More

July 1, 2024

0

Cerevel Therapeutics Announces Positive Results for Tavapadon in Phase 3 Adjunctive Trial for Parkinson’s Disease

Cerevel Therapeutics in the NEWS Cerevel Therapeutics ( CERE ) announced positive topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon, the first and only D1/D5 receptor partial agonist being studied as once a day treatment for Parkinson’s...

Read More

April 20, 2024

0

An Important Reminder from Vir Biotechnology

Vir Biotechnology  Vir Biotechnology ( VIR ) is a commercial-stage immunology firm focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir assembled four technology platforms that stimulate and enhance the immune system by exploiting...

Read More

May 19, 2022

0

INmune Bio Inc. Update on Two Alzheimer Disease Patients Who Continued to Receive XPro Product

INmune Bio Press Release   INmune Bio (NASDAQ: INMB ) is pleased to share an update on two patients from the Phase 1b trial completed in 2021 who have continued to receive XPro™ for treatment of Alzheimer’s Disease ( AD )...

Read More

April 30, 2024

0

Vertex Pharmaceuticals and Type 1 Diabetes

Vertex Pharmaceuticals to Announce New Data on VX-880 Clinical Trial Vertex Pharmaceuticals ( VRTX ) announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes ( T1D ) and its Phase 1/2 trial of...

Read More

May 31, 2022

0

Regeneron: Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness 

Regeneron in the NEWS Regeneron Pharmaceuticals ( REGN ) announced today that the investigational gene therapy DB-OTO improved hearing to normal levels in one child (dosed at 11 months of age) within 24 weeks, and initial hearing improvements were observed...

Read More

May 8, 2024

0

  • Previous
  • 1
  • 2
  • ...
  • 111
  • 112
  • 113
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy